Success Metrics

Active Trials
3(100%)

Phase Distribution

Ph phase_2
1
33%
Ph not_applicable
2
67%

Phase Distribution

0

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
N/ANon-phased studies
2(66.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

3

all time

Status Distribution
Active(3)

Detailed Status

Recruiting3

Development Timeline

Analytics

Development Status

Total Trials
3
Active
3
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 21 (33.3%)
N/A2 (66.7%)

Trials by Status

recruiting3100%

Recent Activity

3 active trials
Showing 3 of 3
recruitingphase_2

ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)

NCT06951646
recruitingnot_applicable

Safety and Efficacy of Adipose-Derived Regenerative Cells (ADRCs) for Improving Hand Dysfunction in Systemic Sclerosis

NCT07360808
recruitingnot_applicable

Effect of Resistance Training in Patients on the Waiting List for Heart Transplant

NCT06426173

Clinical Trials (3)

Showing 3 of 3 trials
NCT06951646Phase 2

ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)

Recruiting
NCT07360808Not Applicable

Safety and Efficacy of Adipose-Derived Regenerative Cells (ADRCs) for Improving Hand Dysfunction in Systemic Sclerosis

Recruiting
NCT06426173Not Applicable

Effect of Resistance Training in Patients on the Waiting List for Heart Transplant

Recruiting

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3